Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1

Biochemical Pharmacology

Volumn 136, Issue , 2017, Pages 99-108

  Hager, Marlies V ^a   Clydesdale, Lachlan ^b   Gellman, Samuel H ^a   Sexton, Patrick M ^b   Wootten, Denise ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Biased agonism; Cell signaling; G protein coupled receptor; Glucagon like peptide 1 receptor; Peptides

Indexed keywords

ALPHA AMINO ACID; BETA AMINO ACID; BETA ARRESTIN 1; BETA ARRESTIN 2; CALCIUM; CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CHO CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; AMINO ACID SEQUENCE; ANIMAL; CRICETULUS; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HAMSTER; HEK293 CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEK293 CELLS; HUMANS; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION;

EID: 85017351662     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.03.018     Document Type: Article

References (46)

1. Zaccardi, F., Webb, D.R., Yates, T., Davies, M.J., Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad. Med. J. 92 (2016), 63–69.
2. DeFronzo, R.A., Pathogensis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35 (1992), 389–397.
3. Hundal, R.S., Inzucchi, S.E., Metformin: new understandings, new uses. Drugs 63 (2003), 1879–1894.
4. Swinnen, S.G., Hoekstra, J.B., DeVries, J.H., Insulin therapy for type 2 diabetes. Diabetes Care 32:Suppl. 2 (2009), S253–259.
5. Holst, J.J., Knop, F.K., Vilsboll, T., Krarup, T., Madsbad, S., Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34:Suppl 2 (2011), S251–257.
6. Baggio, L.L., Drucker, D.J., (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157.
7. Montrose-Rafizadeh, C., Avdonin, P., Garant, M.J., Rodgers, B.D., Kole, S., Yang, H., et al. Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in chinese hamster ovary cells. Endocrinology 140 (1999), 132–1140.
8. Hallbrink, M., Homqvist, T., Olsson, M., Ostenson, C.-G., Efendic, S., Langel, U., Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Gas and Gai/Gao activation. Bichim. Biophys. Acta 1546 (2001), 79–86.
9. Wootten, D., Reynolds, C.A., Smith, K.J., Mobarec, J.C., Koole, C., Savage, E.E., et al. The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism. Cell 165 (2016), 1632–1643.
10. Jorgensen, R., Kubale, V., Vrecl, M., Schwartz, T.W., Elling, C.E., Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s). J. Pharmaocl. Exp. Ther. 322 (2007), 148–154.
11. Sonoda, N., Imamura, T., Yoshizaki, T., Babendure, J.L., Lu, J.C., Olefsky, J.M., Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 6614–6619.
12. Quoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., et al. GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J. Biol. Chem. 285 (2010), 1989–2002.
13. Rajagopal, S., Rajagopal, K., Lefkowitz, R.J., Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9 (2010), 373–386.
14. Reiter, E., Ahn, S., Shukla, A.K., Lefkowitz, R.J., Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52 (2002), 179–197.
15. Kenakin, T., Christopoulos, A., Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12 (2013), 205–216.
16. Kobilka, B.K., Deupi, X., Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 28 (2007), 397–406.
17. Kenakin, T., Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24 (2003), 346–354.
18. Whalen, E.J., Rajagopal, S., Lefkowitz, R.J., Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 17 (2011), 126–139.
19. Appleton, K.M., Luttrell, L.M., Emergent biological properties of arrestin pathway-selective biased agonism. J. Recept. Signal Transduct. Res. 33 (2013), 153–161.
20. Koole, C., Wootten, D., Simms, J., Valant, C., Sridhar, R., Woodman, O.L., et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol. Pharmacol. 78 (2010), 456–465.
21. Wootten, D., Savage, E.E., Willard, F.S., Bueno, A.B., Sloop, K.W., Christopoulos, A., et al. Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. Mol. Pharmacol. 83 (2013), 822–834.
22. Broichhagen, J., Podewin, T., Meyer-Berg, H., von Ohlen, Y., Johnston, N.R., Jones, B.J., et al. Optical control of insulin secretion using an incretin switch. Angew. Chem. Int. Ed. Engl. 54 (2015), 15565–15569.
23. Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P.A., Xie, J., et al. Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects. Nat. Commun., 6, 2015, 8918.
24. Hager, M.V., Johnson, L.M., Wootten, D., Sexton, P.M., Gellman, S.H., Beta-arrestin-biased agonists of the GLP-1 receptor from beta-amino acid residue incorporation into GLP-1 analogues. J. Am. Chem. Soc. 138 (2016), 14970–14979.
25. Wootten, D., Simms, J., Miller, L.J., Christopoulos, A., Sexton, P.M., Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 5211–5216.
26. Johnson, L.M., Barrick, S., Hager, M.V., McFedries, A., Homan, E.A., Rabaglia, M.E., et al. A potent alpha/beta-peptide analogue of GLP-1 with prolonged action in vivo. J. Am. Chem. Soc. 136 (2014), 12848–12851.
27. Denton, E.V., Craig, C.J., Pongratz, R.L., Appelbaum, J.S., Doerner, A.E., Narayanan, A., et al. A beta-peptide agonist of the GLP-1 receptor, a class B GPCR. Org. Lett. 15 (2013), 5318–5321.
28. Bai, X., Niu, Y., Zhu, J., Yang, A.Q., Wu, Y.F., Ye, X.S., A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus. Bioorg. Med. Chem. 24 (2016), 1163–1170.
29. Peggion, E., Mammi, S., Schievano, E., Silvestri, L., Schiebler, L., Bisello, A., et al. Structure-function studies of analogues of parathyroid hormone (PTH)-1-34 containing beta-amino acid residues in positions 11–13. Biochemistry 41 (2002), 8162–8175.
30. Schievano, E., Mammi, S., Carretta, E., Fiori, N., Corich, M., Bisello, A., et al. Conformational and biological characterization of human parathyroid hormone hPTH(1–34) analogues containing beta-amino acid residues in positions 17–19. Biopolymers 70 (2003), 534–547.
31. Cheloha, R.W., Maeda, A., Dean, T., Gardella, T.J., Gellman, S.H., Backbone modification of a polypeptide drug alters duration of action in vivo. Nat. Biotechnol. 32 (2014), 653–655.
32. Olson, K.E., Kosloski-Bilek, L.M., Anderson, K.M., Diggs, B.J., Clark, B.E., Gledhill, J.M. Jr, et al. Selective VIP receptor agonists facilitate immune transformation for dopaminergic neuroprotection in MPTP-intoxicated mice. J. Neurosci. 35 (2015), 16463–16478.
33. Cheloha, R.W., Watanabe, T., Dean, T., Gellman, S.H., Gardella, T.J., Backbone modification of a parathyroid hormone receptor-1 antagonist/inverse agonist. ACS Chem. Biol. 11 (2016), 2752–2762.
34. Horne, W.S., Boersma, M.D., Windsor, M.A., Gellman, S.H., Sequence-based design of alpha/beta-peptide foldamers that mimic BH3 domains. Angew. Chem. Intl. Ed. Engl. 47 (2008), 2853–2856.
35. Steer, D.S., Lew, R.A., Perlmutter, P., Smith, A.I., Aguilar, M.-I., Beta-amino acids: versatile peptidomimetics. Curr. Med. Chem. 9 (2002), 811–822.
36. Koole, C., Wootten, D., Simms, J., Miller, L.J., Christopoulos, A., Sexton, P.M., Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J. Biol. Chem. 287 (2012), 3642–3658.
37. Koole, C., Wootten, D., Simms, J., Valant, C., Miller, L.J., Christopoulos, A., et al. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol. Pharmacol. 80 (2011), 486–497.
38. May, L.T., Avlani, V.A., Langmead, C.J., Herdon, H.J., Wood, M.D., Sexton, P.M., et al. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol. Pharmacol. 72 (2007), 463–476.
39. Savage, E.E., Wootten, D., Christopoulos, A., Sexton, P.M., Furness, S.G., A simple method to generate stable cell lines for the analysis of transient protein-protein interactions. Biotechniques 54 (2013), 217–221.
40. Binkowski, B.F., Butler, B.L., Stecha, P.F., Eggers, C.T., Otto, P., Zimmerman, K., et al. A luminescent biosensor with increased dynamic range for intracellular cAMP. ACS Chem. Biol. 6 (2011), 1193–1197.
41. Jorgensen, R., Martini, L., Schwartz, T.W., Elling, C.E., Characterization of glucagon-like peptide-1 receptor beta-arrestin 2 interaction: a high-affinity receptor phenotype. Mol. Endocrinol. 19 (2005), 812–823.
42. Wheeler, M.B., Lu, M., Dillon, J.S., Leng, X.-H., Chen, C., Boyd, A.E., Functional expression of the rat glucagon-like peptide-1 receptor, and evidence for coupling to both adenylyl cyclase, and phospholipase-C. Endocrinology 133 (1993), 57–62.
43. Holz, G.G., Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53 (2004), 5–13.
44. Thompson, A., Kanamarlapudi, V., Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the Galphaq pathway. Biochem. Pharmacol. 93 (2015), 72–84.
45. Black, J.W., Leff, P., Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220 (1983), 141–162.
46. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., Novick, S., A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3 (2012), 193–203.